U.S., June 18 -- ClinicalTrials.gov registry received information related to the study (NCT07652281) titled 'A Clinical Study of SHR-5421 in Patients With Multiple Myeloma' on June 11.
Brief Summary: This is a Phase I, open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of SHR-5421 in patients with multiple myeloma (MM).
Study Start Date: June, 2026
Study Type: INTERVENTIONAL
Condition:
Multiple Myeloma
Intervention:
DRUG: SHR-5421 for Injection
SHR-5421 for injection.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Published by HT Digital Content Services with permission from Health Daily Digest....